Analysis of Factors Associated With Recurrence of Early-Stage Endometrial Carcinoma and Atypical Endometrial Hyperplasia in Infertile Women After In Vitro Fertilization Treatment

Yaxing Guo†, Xuan Zong†, Hongzhen Li1,2,3,4 and Jie Qiao1,2,3,4*

1 Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China, 2 National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China, 3 Key Laboratory of Assisted Reproduction (Peking University), Ministry of Education, Beijing, China, 4 Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Peking University Third Hospital, Beijing, China

Purpose: To explore the relationship between different artificial reproductive treatment (ART) strategies and tumor outcomes, by analyzing clinical data of patients with endometrial carcinoma (EC) and atypical endometrial hyperplasia (AEH).

Methods: This retrospective study was performed in a tertiary hospital. Patients (n=131) with EC or AEH, who underwent in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment between June 2010 and June 2021, were divided into a recurrence group and a non-recurrence group. Clinical characteristics and tumor outcomes were assessed.

Results: 131 patients were followed up for 4-132 months; 33 patients had recurrence, the recurrence rate was 25.2%, 3-year recurrence-free survival (RFS) rate was 83.2 ± 3.4%, and the 5-year RFS rate was 72.9 ± 4.4%. Factors including the frequency of controlled ovarian stimulation (COS) and the total days of ovarian stimulation had no significant effect on the recurrence of tumor lesions (p=0.368 and 0.969, respectively). Histology type (HR: 4.94, 95%CI: 2.41-10.15, p<0.001) and successful/un successful live birth (HR: 0.30, 95%CI: 0.14-0.65, p=0.003) were independent factors of recurrence.

Conclusions: The degree at which an endometrial lesion progresses into carcinoma is a key factor affecting the recurrence of EC/AEH in patients after IVF/ICSI treatment, and successful live birth is a protective factor for the recurrence of endometrial lesions. Different COS protocols and COS frequencies, as well as the dosage and duration of Gn used during IVF did not affect the recurrence of endometrial lesions.

Keywords: endometrial carcinoma, atypical endometrial hyperplasia, assisted reproductive technology, recurrence, in vitro fertilization
INTRODUCTION

Endometrial cancer (EC) is one of the most common gynecological malignancies worldwide, with more than 410,000 new cases in 2020 (1). Atypical endometrial hyperplasia (AEH) is a precancerous lesion of endometrial carcinoma whose malignant transformation rate is 29%-52% (2). Although EC is often seen in postmenopausal women, approximately 5% of patients are diagnosed before age of 40 years, which includes 70% of childless women (3). The standard management for EC/AEH is hysterectomy and bilateral salpingo-oophorectomy which is not suitable for young patients with fertility desire (4). The effectiveness of conservative treatment in young patients with early-stage endometrial carcinoma (EEC) and AEH has been confirmed with a high complete remission (CR) rate (75-96.5%). However, the rate of recurrence is as high as 26.0-40.6%, and the median recurrence time was 12-28 months (5-7). Patients who underwent standard management for EEC/AEH had better prognosis, with 5- and 10-year survival rates of 99.2% and 98%, respectively (5). The challenge for EEC/AEH patients is how to get a livebirth as early as possible and then to receive the standard management. However, repeated intrauterine operations will lead to increased incidence of thin endometrium and intrauterine adhesions. Ovarian reserve and fertility issues may affect recurrence rate, in order to provide more treatment options, which was defined as maintenance therapy, before referral to REI specialists.

Conservative Treatment

The endometrial lesion of each patient was comprehensively evaluated by the gynecologic oncologist and met the criteria for fertility-sparing treatment. All patients received oral progesterins or intrauterine progesterone therapy including four different treatment regimens as follows: (1) MA at a dose of 160–320 mg per day (n=32); (2) MPA at a dose of 250–500 mg per day (n=95); (3) Gonadotropin-releasing hormone agonist (GnRHa) combined levonorgestrel intrauterine sustained release system (LNG-IUS) (n=2); (4) Intrauterine LNG-IUS alone (n=2). Hysteroscopy and endometrial biopsy were performed every three months to evaluate the treatment response.

Once patients achieved CR, some discontinued MA or MPA, and were referred to the REI specialists directly for ART. Some patients continued to receive the same regimen for another 3–6 months according to different doctors’ opinions, which was defined as maintenance therapy, before referral to REI specialists.

IVF Treatment

A comprehensive evaluation of infertility was performed by a REI specialist for every patient who was referred to the reproduction center. Agonist, antagonist, or mild-stimulation protocols were used for ovarian stimulation in patients who received IVF/ICSI treatment. Gonadotropin (Gn) usage involves follicle stimulating hormone (FSH), human menopausal gonadotropin (HMG), and recombinant follitropin β injection. Agonist protocol includes three different dosage forms of GnRHa as follows: ultra-long protocol, long protocol, and short protocol.

Ultra-long protocol means intramuscular injection of 3.75 mg of long-acting GnRHa was performed on the 1st or 2nd day of the menstrual cycle, and Gn was started 30 days later until the trigger day. Long protocol means intramuscular injection of 1.25 mg long-acting GnRHa was given during the luteal phase of the previous menstrual cycle, and Gn was started 14 days later until the trigger day. Short protocol means intramuscular injection of short-acting GnRHa 0.1 mg/d was started on the 2nd day of the

METHODS

Study Design and Patients

In this single-center retrospective study, we reviewed the medical records of infertile patients with EEC or AEH who underwent IVF after achieving CR at the Reproductive Center of Peking University Third Hospital (PUTH) between June 2010 and June 2021. Follow-up ended on October 31, 2021. This study was approved by the Ethics Committee of the PUTH (No. IRB 00006761-M2021237).

The inclusion criteria were as follows: (1) histologically proven well-differentiated endometrioid EC or AEH, magnetic resonance imaging confirmed no infiltration of myometrium; (2) accepted standard conservative therapy and achieved CR; (3) age ≤40 years old; (4) hysteroscopic evaluation performed and histologically proven normal endometrium before COS; and (5) performed standard COS protocol cycles.

The selection process of the study population is illustrated in Figure 1. Between June 2010 and June 2021, 139 infertile patients with EEC or AEH were referred to our reproductive center after achieving CR. Eight patients were excluded from the study for the following reasons: age >40 years old (n=2), prior history of IVF before conservative treatment (n=2), incomplete medical records (n=4). A total of 131 patients were included in the analysis. Clinical and IVF/ICSI characteristic data were reviewed and extracted from both paper and electronic medical records.

FIGURE 1. Between June 2010 and June 2021, 139 infertile patients with EEC or AEH were referred to our reproductive center after achieving CR. Eight patients were excluded from the study for the following reasons: age >40 years old (n=2), prior history of IVF before conservative treatment (n=2), incomplete medical records (n=4). A total of 131 patients were included in the analysis. Clinical and IVF/ICSI characteristic data were reviewed and extracted from both paper and electronic medical records.
menstrual cycle, and Gn was started on the 3rd day of the menstrual cycle until the trigger day. Antagonist protocol means Gn was started on the 2nd day of the menstrual cycle, and 0.25 mg/d gonadotropin-releasing hormone antagonist (GnRH-A) was added when the dominant follicle diameter was 12-14 mm on the trigger day. Mild-stimulation protocol means that letrozole 2.5 or 5.0 mg/d was given orally from the 2nd to 6th day of the menstrual cycle for 5 days. Meanwhile, intramuscular injection of hMG 75-150 U/d was given from the 3rd day of the menstrual cycle. GnRH-A 0.25 mg/d was added when the diameter of the dominant follicle reached 12-14 mm, until the trigger day. The start dose of Gn is determined by the individual patient (150-300 U/d), and is adjusted according to follicular development in the process of COS. Ovarian follicular development was monitored by TVS, and recombinant human choric gonadotropin (r-hCG) was administered to induce oocyte maturation when at least two leading follicles reached 18 mm in diameter. Oocyte retrieval was performed 34 and 38 h later. Oocytes were fertilized using conventional IVF or ICSI. The development and quality of embryos were assessed on day 3, as previously published, considering the percentage of fragmentation and quality of cytoplasm (10). Top-quality embryos on day 3 were defined as embryos that were derived from 2 PN embryos and could reach 5- to 8-cell stage with cytoplasmic fragmentation of <30% and even blastomeres. Non-top-quality embryos were extensively cultured to the blastocyst stage. Blastocyst morphology was evaluated on day 5 using the Gardner grading system (11). Two top-quality embryos on day 3 or one on day 5 were transferred in the fresh ET cycle. Some patients did not accept fresh ET because of the thin endometrium, a high risk of ovarian hyperstimulation syndrome, or some other reasons. Surplus viable embryos were cryopreserved according to a vitrification protocol and thawed as previously described (12). During frozen-thawed ET (FET) cycles, frozen embryos were transferred on day 3 or 5 throughout the natural or artificial cycles.

Regular luteal support was provided as oral dydrogesterone at 20 mg/d or vaginal administration of progesterone 60 mg/d from the day of ET to throughout the 10th week of gestation.

**Definition of Observation Indicators**

CR was defined as the absence of hyperplasia, cancerous lesions, or other abnormal histological findings. Recurrence was defined as endometrial carcinoma or atypical hyperplasia confirmed by endometrial biopsy that recurred during ART treatment or during follow-up after ART. Treatment duration was calculated as the interval from the start to the end of oral or intrauterine progesterone treatment. The time to CR was calculated as the interval from the start of progesterone treatment to CR. The duration of maintenance therapy was calculated from the date of CR to the end of progesterone treatment. The time to IVF was defined as the interval between the CR and the start of IVF cycle. Live birth was defined as any birth event beyond 28 weeks of gestation, in which at least one neonate was born alive. The cumulative live birth rate (CLBR) of the study cohort was defined as the number of women who achieved a live birth divided by the total study population.

**Statistical Methods**

Continuous data with normal distribution were represented as mean (standard deviation, SD), while continuous data with non-
normal distribution were represented as median (interquartile range, IQR). Continuous data were analyzed using T test and Mann-Whitney U test. Categorical data were expressed as percentages and analyzed using Chi-square test or Fisher exact test. The median recurrence interval and cumulative recurrence rate were calculated using the Kaplan-Meier method, and the difference in recurrence rate was tested with log-rank method. COX regression model was used for correlation analysis of tumor RFS time. All analyses were performed using SPSS software (version 25.0; IBM Corp, Armonk, NY, USA). Significance was defined as a two-sided p-value <0.05.

RESULTS

Baseline Characteristics

Up to October 31, 2021, 131 patients included in the study were followed up for 4.0-132.0 months, with a median follow-up of 50.0 months. As shown in Table 1, the average age of 131 patients was 33.6 ± 3.8 years and the average BMI was 26.0 ± 4.2 Kg/m² with a median infertility time of 4.0 (range: 2.0-6.0) years. Most of the study participants (80.9%) were diagnosed with primary infertility, and 25 patients (19.1%) with secondary infertility. Ovulatory dysfunction and fallopian tube factors were the main causes of infertility, accounting for 38.9% (51 cases) and 24.4% (32 cases), respectively. However, there were no significant differences in the incidence of these complications between the recurrence group and the non-recurrence group (PCOS, DM and hypertension, p=0.827,1.000 and 1.000, respectively). Meanwhile, there were no significant differences in basal sex hormone levels (LH, E2 and FSH, p=0.419, 0.654 and 0.824, respectively) and basal Antral follicle count (AFC) (p=0.850) between the two groups.

In total, 131 patients underwent an average of 1.6 ± 0.9 COS cycles and 1.8 ± 1.2 embryo transfers (ETs), and there was no significant difference in the number of COS cycles between the recurrence group and the non-recurrence group (p=0.521). Each patient received 3600.0 (range: 2100.0-5268.8) IU of Gn in all COS cycles, and the total number of days of Gn injection was 14.0 (range: 11.0-24.0).

| Characteristics | Total (n=131) | Non-recurrence (n=98) | Recurrence (n=33) | p value |
|-----------------|--------------|-----------------------|-------------------|--------|
| Age, mean (SD), years | 33.6 (3.8) | 33.7 (3.8) | 33.6 (4.0) | 0.420 |
| BMI, mean (SD), Kg/m² | 26.0 (4.2) | 26.1 (4.1) | 25.7 (4.7) | 0.861 |
| Histology type, n (%) | 0.001* | 0.001* | 0.001* | 0.001* |
| EC | 30 (22.9) | 15 (15.3) | 15 (45.5) | 0.001* |
| AEH | 101 (77.1) | 83 (84.7) | 18 (54.5) | 0.001* |
| Type of infertility, n (%) | 0.614 | 0.614 | 0.614 | 0.614 |
| Primary | 106 (80.9) | 78 (79.6) | 28 (84.8) | 0.614 |
| Secondary | 25 (19.1) | 20 (20.4) | 5 (15.2) | 0.614 |
| Duration of infertility, median (IQR), years | 4.0 (2.0-6.0) | 4.0 (2.0-6.0) | 4.0 (2.0-6.5) | 0.924 |
| Causes of infertility, n (%) | 0.192* | 0.192* | 0.192* | 0.192* |
| Male factors | 15 (11.5) | 9 (9.2) | 6 (18.2) | 0.827 |
| Tubal factors | 32 (24.4) | 24 (24.5) | 8 (24.2) | 0.827 |
| Ovarian factors | 51 (38.9) | 41 (41.8) | 10 (30.3) | 0.827 |
| Uterine factors | 5 (3.8) | 2 (2.0) | 3 (9.1) | 0.827 |
| Unknown factors | 28 (21.4) | 22 (22.4) | 6 (18.2) | 0.827 |
| Complications, n (%) | 0.827 | 0.827 | 0.827 | 0.827 |
| PCOS | 33 (25.3) | 30 (26.1) | 9 (23.1) | 0.827 |
| DM | 12 (9.2) | 9 (9.2) | 3 (9.1) | 1.000* |
| Hypertension | 7 (5.3) | 5 (5.1) | 2 (6.1) | 1.000* |
| Ovarian reserve, median (IQR) | 0.976 | 0.976 | 0.976 | 0.976 |
| AMH (ng/mL) | 1.1 (0.4-2.1) | 1.1 (0.5-1.7) | 1.2 (0.3-2.5) | 0.976 |
| No. of basal AFC | 7.0 (4.0-13.0) | 7.0 (4.0-14.0) | 7.0 (5.0-10.0) | 0.850 |
| Basal LH, median (IQR), mIU/mL | 1.8 (0.6-4.0) | 1.9 (0.8-4.0) | 1.7 (0.5-3.2) | 0.419 |
| Basal FSH, median (IQR), mIU/mL | 6.0 (4.4-8.1) | 6.1 (4.5-8.1) | 6.0 (4.4-8.1) | 0.824 |
| Basal E₂, median (IQR), pmol/L | 131.0 (92.5-128.5) | 128.5 (89.7-172.0) | 132.0 (104.5-177.5) | 0.654 |
| No. of COS cycles, mean (SD) | 1.6 (0.9) | 1.6 (0.9) | 1.5 (0.8) | 0.521 |
| No. of ET cycles, mean (SD) | 1.8 (1.2) | 1.8 (1.2) | 1.9 (1.1) | 0.382 |
| Total dose of Gn, median (IQR), IU | 3600.0 (2100.0-5268.8) | 3550.0 (2206.3-5687.5) | 3750.0 (2087.5-5025.0) | 0.994 |
| No. of days of ovarian stimulation, median (IQR) | 14.0 (11.0-24.0) | 14.0 (10.0-24.0) | 14.0 (12.0-24.0) | 0.493 |
| With a livebirth, n (%) | 66 (49.6) | 57 (58.2) | 9 (27.3) | 0.003* |

BMI, body mass index; EC, endometrial carcinoma; AEH, atypical endometrial hyperplasia; AMH, anti-mullerian hormone; AFC, antral follicle count; E₂, estradiol; CR, complete remission; IVF, in vitro fertilization; SD, standard deviation; Gn, gonadotropin; IQR, interquartile range; FSH, follicle-stimulating hormone; LH, luteinizing hormone; PCOS, Polycystic ovary syndrome; DM, Diabetes mellitus; COS, controlled ovarian stimulation; ET, embryo transfer.

*p<0.05.

Fisher’s exact test.
Recurrence occurred in 15 of 30 EC patients and 18 of 101 AEH patients, with a significantly higher recurrence rate in the EC group than in the AEH group (50.0% vs 17.8%, \( p = 0.001 \)). The proportion of patients who achieved a live birth was significantly different between the two groups (\( p = 0.003 \)).

### Characteristics of Conservative Treatment

According to Table 2, there were four conservative treatment regimens including 95 patients (72.5%) using MPA and 32 patients (24.4%) using MA. Both GnRHa combined with LNG-IUS and LNG-IUS alone were reported in 2 patients (1.5%), and there was a significant difference between the different regimens used in the recurrence and non-recurrence groups (\( p = 0.021 \)). The mean treatment duration was 7.2 months, and the treatment duration in the recurrence group was significantly longer than that in the non-recurrence group (8.6 vs 6.7 months, \( p = 0.023 \)). The number of hysteroscopic operations in the recurrence group was also significantly higher than that in the non-recurrence group (4.0 vs 3.0 times, \( p < 0.001 \)). The mean CR time and the median time to IVF in the recurrence group was not significantly different from that in the non-recurrence group.

Among 33 patients with recurrence, 12 patients with EC pathology after recurrence received comprehensive staging operation, 3 patients with AEH underwent hysterectomy, and 18 patients received conservative treatment again (12 with MPA, 3 with MA, 2 with MPA+LNG-IUS, and 1 with GnRHa+LNG-IUS). Fifteen patients achieved CR again and three were still on treatment. Three patients in the non-recurrence group underwent hysterectomy after delivery.

### Factors Associated With Recurrence

Up to October 31, 2021, 33 of 131 patients had recurrence during follow-up, with a 3-year RFS rate of 82.2 ± 3.4% and a 5-year RFS rate of 72.9 ± 4.4%. Four of 131 patients with less than 12 months of follow-up were excluded, and 127 patients were finally included in the COX regression analysis.

As shown in Table 3, continuous variables were converted to categorical variables based on clinical experience and related literature reports. Univariate COX regression analysis was conducted and showed that the type of histology (HR: 5.56, 95%CI: 2.73-11.33, \( p < 0.001 \)), maintenance therapy before IVF (HR: 2.03, 95%CI: 1.01-4.09, \( p = 0.047 \)) were associated with a higher recurrence rate. Patients who successfully achieved a live birth had a significantly lower recurrence rate (HR: 0.27, 95%CI: 0.12-0.58, \( p = 0.001 \)). There were no significant differences in recurrence rates among patients receiving different conservative treatments (\( p = 0.800 \)).

The number of COS cycles, basal E2 level, total dose of Gn, and total days of ovarian stimulation had no significant effect on the recurrence rate of EC/AEH (\( p = 0.521, 0.785, 0.711, \) and 0.586, respectively).

As shown in Table 3, we included 9 variables (age, BMI, histology type, number of COS cycles, maintenance treatment before IVF, total days of ovarian stimulation, time to IVF, with livebirth, and clinical intervention after IVF and delivery) based on the COX univariate regression analysis, clinical experience, and published literature into COX regression model for multivariate analysis, and found that histology type (HR: 4.94, 95%CI: 2.41-10.15, \( p < 0.001 \)) and livebirth or not (HR: 0.30, 95% CI: 0.14-0.65, \( p = 0.003 \)) were independent influencing factors of recurrence. The influence on RFS of EC or AEH, for livebirth or not are shown in Figure 2.

### Different COS Protocols and Tumor Recurrence

As shown in Figure 1, 82 of 131 patients received a single COS cycle, they included 64 (78.0%) AEH patients and 18 (22.0%) EC patients. These 82 patients were summarized and analyzed using different COS protocols.

82 patients were followed up for 13.0-128.0 months. By the time of follow-up, 22 of the 82 patients had recurrence, and the 3-year RFS rate was 81.0 ± 4.6%, and the 5-year RFS rate was 73.6 ± 5.5%. As...
showed in Table 4, all 82 patients received conventional COS protocols, among which more patients adopted agonist protocol and antagonist protocol, accounting for 47.6% and 40.2%, respectively. Different protocols had no significant effect on recurrence (p=0.683). The start dose and total dose of Gn in the recurrence group were slightly higher than those in the non-recurrence group; however, the difference was not significant (212.5 vs 200.0 IU, p=0.797; 2650.0 vs 2550.0 IU, p=0.802). In addition, there was no significant difference in serum E2 level on the trigger day between the two groups (3880.5 vs 4678.5 pmol/L, p=0.530).

As shown in Table 5, we included 8 variables (age, BMI, histology type, protocols of COS, total dosage of Gn, E2 level on trigger day, maintenance treatment before IVF, and with livebirth or not) into the COX regression model for

| Table 3 | Univariate and multiple COX regression analysis of factors associated with recurrence. |
|----------------|---------------------------------|----------------|----------------|----------------|----------------|
| Variables                  | Univariate analysis             | Multiple analysis                  |
|                           | HR (95%CI)                      | p value                  | HR (95%CI)                      | p value                  |
| Age (years)                |                                 |                            | 0.181                        | 0.310                  |
| ≤35                        | 1                               |                            | 1                           |                        |
| >35                        | 0.59 (0.28-1.28)                 | 0.758                      | 0.66 (0.26-1.65)              | 0.693                  |
| BMI (Kg/m²)                |                                 |                            | 1                           |                        |
| ≤25.0                      | 1                               |                            | 1                           |                        |
| >25.0                      | 1.12 (0.56-2.22)                 | 1.06 (0.48-2.36)           | 1                           |                        |
| Histological type          |                                 |                            | <0.001*                      | <0.001*                  |
| AEH                        | 1                               |                            | 1                           |                        |
| EC                         | 5.56 (2.73-11.33)                | 4.94 (2.41-10.15)          |                            |                        |
| Basal E2 (pmol/L)          |                                 |                            | 0.785                        | 0.785                  |
| ≤165.0                     | 1                               |                            | 1                           |                        |
| >165.0                     | 1.11 (0.53-2.33)                 | 1.02 (0.28-3.81)           | 1                           |                        |
| Treatment duration (months)|                                 |                            | 0.192                        | 0.192                  |
| ≤6.0                       | 1                               |                            | 1                           |                        |
| >6.0                       | 1.60 (0.79-3.21)                 | 1.74 (0.47-6.48)           | 1                           |                        |
| Time to CR (months)        |                                 |                            | 0.382                        | 0.382                  |
| ≤3.0                       | 1                               |                            | 1                           |                        |
| >3.0                       | 1.37 (0.68-2.75)                 | 1.63 (0.56-4.81)           | 1                           |                        |
| Maintenance therapy before IVF |                                 |                            | 0.047*                      | 0.047*                  |
| No                        | 1                               |                            | 1                           |                        |
| Yes                       | 2.03 (1.01-4.09)                 | 1.63 (0.58-4.63)           | 1                           |                        |
| Recurrence before IVF     |                                 |                            | 0.168                        | 0.168                  |
| No                        | 1                               |                            | 1                           |                        |
| Yes                       | 1.75 (0.79-3.88)                 | 1.75 (0.79-3.88)           | 1                           |                        |
| Time to IVF (months)       |                                 |                            | 0.637                        | 0.637                  |
| ≤3.0                       | 1                               |                            | 1                           |                        |
| 3.0-6.0                    | 1.02 (0.28-3.81)                 | 1.74 (0.47-6.48)           | 1                           |                        |
| 6.0-9.0                    | 1.74 (0.47-6.48)                 | 1.63 (0.56-4.81)           | 1                           |                        |
| Conservative treatment    |                                 |                            | 0.080                        | 0.080                  |
| MPA                       | 1                               |                            | 1                           |                        |
| MA                        | 1.92 (0.91-4.05)                 | 7.50 (1.71-32.86)          | 2.15 (0.29-16.11)            |                        |
| GnRHa+LNG-IUS              | 0.711                           |                            | 0.711                        | 0.711                  |
| LNG-IUS                   | 1                               |                            | 1                           |                        |
| Total dose of Gn (IU)     |                                 |                            | 0.586                        | 0.586                  |
| ≤3600.0                   | 1                               |                            | 1                           |                        |
| >3600.0                   | 1.14 (0.57-2.26)                 | 1.21 (0.61-2.39)           | 2.03 (0.55-7.49)             | 2.03 (0.55-7.49)       |
| Total days of ovarian stimulation |                                 |                            | 0.521                        | 0.521                  |
| ≤14.0                     | 1                               |                            | 1                           |                        |
| >14.0                     | 1.21 (0.61-2.39)                 | 0.79 (0.38-1.63)           | 0.79 (0.38-1.63)             | 0.79 (0.38-1.63)       |
| No. of COS cycles         |                                 |                            | 0.001*                       | 0.001*                  |
| ≤1                        | 1                               |                            | 1                           |                        |
| >1                        | 0.79 (0.38-1.63)                 | 0.32 (0.08-1.23)           | 0.32 (0.08-1.23)             | 0.32 (0.08-1.23)       |
| With livebirth            |                                 |                            | 0.001*                       | 0.001*                  |
| No                        | 1                               |                            | 1                           |                        |
| Yes                       | 0.27 (0.12-0.57)                 | 0.30 (0.14-0.65)           | 0.30 (0.14-0.65)             | 0.30 (0.14-0.65)       |
| Clinical intervention after IVF or delivery |                                 |                            | 0.582                        | 0.582                  |
| No                        | 1                               |                            | 1                           |                        |
| Yes                       | 0.75 (0.26-2.13)                 | 1.30 (0.38-4.45)           | 1                           |                        |

BMI, body mass index; EC, endometrial carcinoma; AEH, atypical endometrial hyperplasia; E2, estradiol; AMH, anti-mullerian hormone; CR, complete remission; IVF, in vitro fertilization; Gn, gonadotropin; COS, controlled ovarian stimulation; IVF, in vitro fertilization; CI, confidence interval; HR, hazard ratio; MPA, medroxyprogesterone acetate; MA, megestrol acetate; GnRHa, gonadotropin-releasing hormone agonist; LNG-IUS, levonorgestrel-releasing intrauterine system.

*p<0.05.
multivariate analysis, and found that histology type (HR: 4.48, 95%CI: 1.74-11.57, \( p = 0.002 \)) and with live birth or not (HR: 0.33, 95%CI: 0.12-0.87, \( p = 0.024 \)) were independent influencing factors of recurrence. Different protocols had no significant effect on the recurrence of EC/AEH (\( p = 0.326 \)).

**Pregnancy Outcomes**

In total, 66 of the 131 patients achieved a livebirth, with a CLBR of 50.4% (66/131). Fifty-six cases achieved livebirths by IVF/ICSI method and 6 cases through natural pregnancy after ART termination, as well as 3 by preimplantation genetic diagnostic (PGD) cycle, and 1 by *in vitro* maturation (IVM) method. Five delivered twins and four delivered twice, giving birth to 75 live babies.

**DISCUSSION**

In this single-center retrospective study, we shared our experience of IVF treatment in patients with EEC or AEH.
after conservative treatment. To the best of our knowledge, this is one of the largest studies to focus on IVF treatment and recurrence outcomes of patients with EEC or AEH.

According to current reports, the overall recurrence rate of EC/AEH after conservative treatment is 35.0-62.2% (13, 14), and the recurrence rate of EC/AEH patients after ART treatment is 21.0-47.0% with median recurrence time of 12-28 months (15–19). In this study, the recurrence rate was 25.2% and the median recurrence time was 31.0 (range: 22.5-46.0) months, which is consistent with current reports on recurrence in EC/AEH patients after ART treatment. Also, the overall recurrence rate is not significantly higher than that of EC/AEH patients who received conservative treatment. This once again confirmed the safety and necessity of ART for EC/AEH patients. Also, this study reaffirmed that endometrial cancer is an independent risk factor for recurrence, which is consistent with studies have been reported. In general, the

| Variables | Univariate analysis | Multiple analysis |
|-----------|--------------------|-------------------|
|           | HR (95% CI)        | p value           | HR (95% CI)        | p value |
| Age (years) |                   |                   |                   |         |
| ≤35        | 1                  | 0.995             | 1                 | 0.942   |
| >35        | 1.00 (0.42-2.40)   | 0.699             | 1.09 (0.36-3.28)  | 0.889   |
| BMI (kg/m²) |                   |                   |                   |         |
| ≤25.0      | 1.18 (0.51-2.73)   | 0.001*            | 1.87 (0.57-6.12)  | 0.002*  |
| >25.0      |                    |                   |                   |         |
| Histological type |          |                   |                   |         |
| AEH        | 1                  |                   | 1                  |         |
| EC         |                    |                   | 6.08 (2.37-15.61) | 4.48 (1.74-11.57) |
| Treatment duration (months) |           |                   |                   |         |
| ≤6.0       | 2.27 (0.97-5.34)   | 0.463             |                   |         |
| >6.0       |                    |                   |                   |         |
| Time to CR (months) |          |                   |                   |         |
| ≤3.0       | 1.01 (0.43-2.33)   | 0.004*            | 2.17 (0.47-10.17) |         |
| >3.0       |                    |                   |                   |         |
| Maintenance therapy before IVF |         |                   |                   |         |
| No         | 3.79 (1.54-9.35)   |                   |                   |         |
| Yes        |                    |                   |                   |         |
| Recurrence before IVF |          |                   |                   |         |
| No         | 2.51 (1.07-5.88)   |                   |                   |         |
| Yes        |                    |                   |                   |         |
| Time to IVF (months) |          |                   |                   |         |
| ≤3.0       | 1                  |                   | 0.73 (0.28-1.85)  | 0.31 (0.08-1.20) |
| >3.0       | 0.57 (0.10-3.43)   |                   | 1.15 (0.32-4.08)  | 0.26 (0.04-1.70) |
| Starting dose of Gn (IU) |          |                   |                   |         |
| ≤200.0     | 0.96 (0.42-2.22)   | 0.924             | 1                  | 0.326   |
| >200.0     |                    |                   |                   |         |
| Total dose of Gn (IU) |          |                   |                   |         |
| ≤2500.0    | 0.99 (0.43-2.30)   | 0.979             | 0.99 (0.23-3.47)  | 0.889   |
| >2500.0    |                    |                   |                   |         |
| Total days of ovarian stimulation (days) |           |                   |                   |         |
| ≤12        | 1.00 (0.41-2.45)   | 0.425             | 0.634             | 0.024*  |
| >12        |                    |                   |                   |         |
| E2 on trigger day (pmol/L) |          |                   |                   |         |
| ≤4500.0    | 0.71 (0.31-1.65)   | 0.89 (0.23-3.47)  | 0.25 (0.10-0.65)  | 0.33 (0.12-0.87) |
| >4500.0    |                    |                   |                   |         |
| With livebirth |          |                   |                   |         |
| No         | 1                  |                   |                   |         |
| Yes        | 0.25 (0.10-0.65)   |                   |                   |         |
| Clinical intervention after IVF or delivery |         |                   |                   |         |
| No         | 1                  |                   |                   |         |
| Yes        |                    |                   |                   |         |

BMI, body mass index; EC, endometrial carcinoma; AEH, atypical endometrial hyperplasia; E2, estradiol; CR, complete remission; IVF, in vitro fertilization; Gn, gonadotropin; COS, controlled ovarian stimulation; IVF, in-vitro fertilization; CI, confidence interval; HR, hazard ratio.

*p<0.05.
higher the grade of the lesion, the longer the patient needs to receive conservative treatment, and the more frequent intrauterine operations are required to evaluate the endometrial lesion during this period. So it explains why our analysis found that the conservative regimen duration and the number of hysteroscopic operations were higher in the recurrence group.

Although many studies have confirmed the safety of ART (20, 21), there are still many opposing opinions that COS may increase the recurrence of EC/AEH lesions (22, 23). It is well known that the COS process involves the use of high dosage Gn, and the level of serum estrogen is supraphysiological which may lead to the recurrence of the tumor lesion. Therefore, there is no definite conclusion on the choice of COS protocols for EC/AEH patients. Most REI doctors tend to choose COS protocols which combine letrozole with Gn and can reduce the estrogen level during COS process for EC/AEH patients with reproductive needs (24). However, the mild stimulation protocol usually has lower oocyte retrieval rate and fewer available embryos, and the possibility of a satisfactory pregnancy outcome is relatively low (25). Kalogiannidis proposed that GnRH-a can be used for conservative treatment of AEH due to its inhibitory effect on the endometrium, and long-term down-regulation can reduce the large dose drug accumulation effect on progeny (26). Considering this opinion, GnRH-a protocol may be beneficial in preventing the recurrence of EC/AEH lesions. However, Ichinose reported that the high level of serum estrogen after ovulation induction in EC/AEH patients did not increase recurrence (17). In our study, 82 patients who received only one COS cycle were screened for correlation analysis between different COS protocols and recurrence and it was found that compared to the mild stimulation protocol recommended by most scholars, there was no significant difference in recurrence rate among the three protocols (p=0.326). It can be considered that in terms of COS protocols for EC/AEH patients with reproductive needs, REI doctors have more choices based on oocyte retrieval rate, available embryos rate, clinical pregnancy rate, and live birth rate.

Our study found that the recurrence rate for patients with multiple COS cycles was not higher than that for patients with single COS cycles. We can consider that increase in COS cycles will not lead to an increase in the recurrence rate of tumor lesions. Current studies suggest that the recurrence of endometrial lesions requires long-term stimulation of estrogen, while estrogen levels only show short-term increases during COS, thus not increasing the risk of recurrence (17, 27), which supports the conclusion of our study. Of course, the analysis of COS frequency in this paper still has some limitations. Tumor outcomes were not analyzed for specific different times, but were only done with the classification of single and multiple times due to the limitation of sample. Currently, the number of EC/AEH patients receiving ART in a single center is relatively small. In future, multi-center clinical studies should be carried out to expand the sample size and provide more reliable evidence for current research theories.

Gn plays an important role in the process of COS, which is a key step in ART, to promote the development of dominant follicles and increase the number of oocytes retrieved. No matter the difference in frequency of COS or different COS protocols, it can be reflected in the duration and dose of Gn treatment in the ART process. It has been proven that different usage of Gn will lead to a great difference in serum E2 level, which may affect the outcomes of IVF pregnancy as well as the recurrence of tumor lesion (28). But there was no research analyzed the correlation of the use of Gn and recurrence of tumors in EC/AEH patients. Our analysis showed that there was no significant correlation between the total dose of Gn, duration of Gn used, basal E2 level on trigger day, and tumor recurrence. This result supports that the routine COS protocols in EC/AEH patients with reproductive needs does not increase the risk of tumor recurrence.

Many studies have reported the relationship between pregnancy and tumor recurrence, and found that the recurrence rate in patients who achieved live births was significantly lower than that in patients who did not, suggesting that pregnancy is a protective factor for tumor lesions (16, 21, 29). Similarly, among the 131 patients in this study, the recurrence rate of patients without live births is significantly higher than that of patients with live births (36.9% vs 13.6%, p=0.003). The result was consistent with literature reports. On one hand, the high level of progesterone during pregnancy as well as delivery and the complete decidual detachment from the uterus in the puerperium played a role similar to shaving the tumor lesions, which may prevent the recurrence of the lesion. On the other hand, pregnant women with obesity and PCOS can avoid exposure to estrogen alone for a certain period of time and delay the tumor recurrence and progression (29, 30). However, the above theory is our speculation. There was no study that confirmed that the mechanism of pregnancy can prevent the recurrence of EC/AEH lesions.

Patients were followed up by a gynecologic oncologist after childbirth. We suggest the patient undertake standard management including hysterectomy and bilateral salpingo-oophorectomy. However, if the patients still have a strong desire to preserve their fertility, they can choose to regularly take short-acting contraceptives or intrauterine LNG-IUS. And these patients are supposed to be followed up every three months. In our study, only two patients in the non-recurrence group underwent surgery after childbirth. Therefore, we consider that most patients are unwilling to undergo the hysterectomy. Due to the limited sample size, although we found that there was no significant effect of clinical intervention after IVF or delivery on tumor recurrence, the optimal management of these patients remains to be explored.

This study had some limitations. First, this was a retrospective study conducted in a single center; therefore, selection bias may have occurred. Second, conservative treatment of EC is mostly limited to patients with lesions confined to the endometrium. It is unknown whether the moderately-differentiated tumor, invasion of the muscle layer, and tumor size will affect the prognosis of EC patients after IVF treatments. Prospective studies with larger sample sizes are needed to answer these questions in the future.
CONCLUSION
The degree of the progression of an endometrial lesion into carcinoma is a key factor affecting recurrence in EC/AEH patients after IVF/ICSI treatment; successful live birth is a protective factor against the recurrence of endometrial lesions. Different COS protocols and COS frequencies, as well as different doses and duration of Gn used during ART, did not affect the recurrence of endometrial lesions.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The studies involving human participants were reviewed and approved by Ethics Committee of the Peking University Third Hospital (No: IRB 00006761-M2021237). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

REFERENCES
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660
2. Kurman RJ, Kaminski PF, Norris HJ. The Behavior of Endometrial Hyperplasia. A Long-Term Study of “Untreated” Hyperplasia in 170 Patients. Cancer (1985) 56(2):403–12. doi: 10.1002/1097-0142(19850715) 56:2<403::aid-cncr2820560233>3.0.co;2-x
3. Lucchini SM, Esteban A, Nigra MA, Palacios AT, Alzate-Granados JP, Borla HF. Updates on Conservative Management of Endometrial Cancer in Patients Younger Than 45 Years. Gynecol Oncol (2021) 161(3):802–9. doi: 10.1016/j.ygyno.2021.04.017
4. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP Guidelines for the Management of Patients With Endometrial Carcinoma. Radiother Oncol (2021) 154:327–53. doi: 10.1016/j.radonc.2020.11.018
5. Kalogerou E, Dowdy SC, Bakkum-Gamez JN. Preserving Fertility in Young Patients With Endometrial Cancer: Current Perspectives. Int J Womens Health (2014) 6:991–701. doi: 10.2147/IJWH.S67232
6. Fan Z, Li H, Hu R, Liu Y, Liu X, Gu L. Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. Int J Gynecol Cancer (2018) 28(2):385–93. doi: 10.1097/IGC.0000000000001164
7. Masciullo V, Trivellizzi N, Zannoni G, Catena U, Moroni R, Fanfani F, et al. Prognostic Impact of Hysteroscopic Resection of Endometrial Atypical Hyperplasia-Endometrial Intraepithelial Neoplasia and Early-Stage Cancer in Combination With Megestrol Acetate. Am J Obstet Gynecol (2021) 224 (4):408–10. doi: 10.1016/j.ajog.2020.12.1210
8. Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, et al. National Patterns of Care and Fertility Outcomes for Reproductive-Aged Women With Endometrial Cancer or Atypical Hyperplasia. Am J Obstet Gynecol (2019) 221(5):474.e1–474.e11. doi: 10.1016/j.ajog.2019.05.029
9. Zhou R, Yang Y, Lu Q, Wang J, Miao Y, Wang S, et al. Prognostic Factors of Oncological and Reproductive Outcomes in Fertility-Sparing Treatment of Complex Atypical Hyperplasia and Low-Grade Endometrial Cancer Using Oral Progestin in Chinese Patients. Gynecol Oncol (2015) 139(3):424–8. doi: 10.1016/j.ygyno.2015.09.078

AUTHOR CONTRIBUTIONS
YG, XZ, HL, and JQ developed the design of the study. YG and XZ collected the clinical data. YG drafted the manuscript and contributed the data analysis. XZ, HL, and JQ proofread and revised the manuscript. All authors read and approved the final manuscript.

FUNDING
This study was supported by grants from CAMS Innovation Fund for Medical Sciences (2019-I2M-5-001) and the National Key Research and Development Program of China (2018YFC1002101).

ACKNOWLEDGMENTS
We thank all the staffs in the reproductive center of PUTH for their work for this study.

10. Alpha Scientists in Reproductive, M and E.S.I.G.o. Embryology. The Istanbul Consensus Workshop on Embryo Assessment: Proceedings of an Expert Meeting. Hum Reprod (2011) 26(6):1270–83. doi: 10.1093/humrep/det001
11. Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst Score Affects Implantation and Pregnancy Outcome: Towards a Single Blastocyst Transfer. Fertil Steril (2003) 73(6):1155–8. doi: 10.1016/S0015-0282(03)00518-5
12. Zheng X, Chen Y, Yan J, Wu Y, Zhuang X, Lin S, et al. Effect of Repeated Cryopreservation on Human Embryo Developmental Potential. Reprod BioMed Online (2017) 35(6):627–32. doi: 10.1016/j.rbmo.2017.08.016
13. Inoue O, Hamatani T, Susumu N, Yamagami W, Ogawa S, Takekoto T, et al. Factors Affecting Pregnancy Outcomes in Young Women Treated With Fertility-Preserving Therapy for Well-Differentiated Endometrial Carcinoma or Atypical Endometrial Hyperplasia. Reprod Biol Endocrinol. (2016) 14:2. doi: 10.1186/s12958-015-0136-7
14. Yamazawa K, Hirai M, Fujito A, Nishi H, Terauchi F, Ishikura H, et al. Fertility-Preserving Treatment With Progestin, and Pathological Criteria to Predict Responses, in Young Women With Endometrial Cancer. Hum Reprod (2007) 22(7):1953–8. doi: 10.1093/humrep/dem088
15. Fujimoto A, Ichinose M, Harada M, Hirata Y, Osuga Y, Fujii T. The Outcome of Infertility Treatment in Patients Undergoing Assisted Reproductive Technology After Conservative Therapy for Endometrial Cancer. J Assist Reprod Genet (2014) 31(9):1189–94. doi: 10.1007/s10815-014-0297-x
16. Chae SH, Shim SH, Lee SJ, Lee JY, Kim SN, Kang SB. Pregnancy and Oncologic Outcomes After Fertility-Sparing Management for Early Stage Endometrioid Endometrial Cancer. Int J Gynecol Cancer (2019) 29(1):77–85. doi: 10.1136/ijgc-2018-00036
17. Ichinose M, Fujimoto A, Osuga Y, Minaguchi T, Kawai K, Kano T, et al. The Influence of Infertility Treatment on the Prognosis of Endometrial Cancer and Atypical Complex Endometrial Hyperplasia. Int J Gynecol Cancer (2013) 23 (2):288–93. doi: 10.1097/IGC.0b013e31827c18a1
18. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer Statistics in China, 2015. CA Cancer J Clin (2016) 66(2):115–32. doi: 10.3322/cac2.11338
19. Gallos ID, Yap J, Rajkhowa M, Luesley DM, Coomarasamy A, Gupta JK. Regression, Relapse, and Live Birth Rates With Fertility-Sparing Therapy for Endometrial Cancer and Atypical Complex Endometrial Hyperplasia: A Systematic Review and Metaanalysis. Am J Obstet Gynecol (2012) 207 (4):266.e1–12. doi: 10.1016/j.ajog.2012.08.011
20. Chao AS, Chao A, Wang CJ, Lai CH, Wang HS. Obstetric Outcomes of Pregnancy After Conservative Treatment of Endometrial Cancer: Case Series and Literature Review. *Taiwan J Obstet Gynecol* (2011) 50(1):62–6. doi: 10.1016/j.tjog.2009.10.006

21. Fan Y, Li X, Wang J, Wang Y, Tian L, Wang J. Analysis of Pregnancy-Associated Factors After Fertility-Sparing Therapy in Young Women With Early Stage Endometrial Cancer or Atypical Endometrial Hyperplasia. *Reprod Biol Endocrinol* (2021) 19(1):118. doi: 10.1186/s12958-021-00808-y

22. Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, et al. Uterine Cancer After Use of Clomiphene Citrate to Induce Ovulation. *Am J Epidemiol* (2005) 161(7):607–15. doi: 10.1093/aje/kwi084

23. Silva Idos S, Wark PA, McCormack VA, Mayer D, Overton C, Little V, et al. Ovulation-Stimulation Drugs and Cancer Risks: A Long-Term Follow-Up of a British Cohort. *Br J Cancer* (2009) 100(1):1824–31. doi: 10.1038/sj.bjc.6605086

24. Azim A, Oklay K. Letrozole for Ovulation Induction and Fertility Preservation by Embryo Cryopreservation in Young Women With Endometrial Carcinoma. *Fertil Steril* (2007) 88(3):657–64. doi: 10.1016/j.fertnstert.2006.12.068

25. Liu X, Li T, Wang B, Xiao X, Liang X, Huang R. Mild Stimulation Protocol vs Conventional Controlled Ovarian Stimulation Protocol in Poor Ovarian Response Patients: A Prospective Randomized Controlled Trial. *Arch Gynecol Obstet* (2020) 301(5):1331–9. doi: 10.1007/s00404-020-05513-6

26. Kalogiannidis I, Agorastos T. Conservative Management of Young Patients With Endometrial Highly-Differentiated Adenocarcinoma. *J Obstet Gynaecol* (2011) 31(1):13–7. doi: 10.3109/01443615.2010.532249

27. Park JY, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, et al. Pregnancy Outcomes After Fertility-Sparing Management in Young Women With Early Endometrial Cancer. *Obstet Gynecol* (2013) 121(1):136–42. doi: 10.1097/AOG.0b013e31827a0643

28. Danforth DR. Endocrine and Paracrine Control of Oocyte Development. *Am J Obstet Gynecol* (1995) 172(2 Pt 2):747–52. doi: 10.1016/0002-9378(95)90148-5

29. Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Long-Term Oncologic Outcomes After Fertility-Sparing Management Using Oral Progestin for Young Women With Endometrial Cancer (KGOG 2002). *Eur J Cancer* (2013) 49(4):868–74. doi: 10.1016/j.ejca.2012.09.017

30. Signorelli M, Caspani G, Bonazzi C, Chiappa V, Perego P, Mangioni C. Fertility-Sparing Treatment in Young Women With Endometrial Cancer or Atypical Complex Hyperplasia: A Prospective Single-Institution Experience of 21 Cases. *BJOG* (2009) 116(1):114–8. doi: 10.1111/j.1471-0528.2008.02024.x

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Guo, Zong, Li and Qiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.